AstraZeneca ‘Particularly Pleased’ With Q1 China Performance

AstraZeneca put in another good performance in the emerging markets and China in the first quarter, albeit at lower growth rates than last year, and in contrast to some of its competitors sees continued bright prospects in the latter market in particular, given a well-suited product portfolio.